All In Biotech

Drug Trial Radar · NCT06852768

Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)

A Double-Masked, Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of d-MAPPS™ Ophthalmic Solution in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)

Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Jan 10, 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Feb 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Double-Masked, Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of d-MAPPS™ Ophthalmic Solution in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGHVD)

Conditions

  • oGHVD

Interventions

  • d-MAPPSBiological

    Based on randomization d-MAPPS, will be self-administered, 2 drops into each eye four times a day (QID) a day for ninety (90) days.

  • PlaceboBiological

    Based on randomization, Placebo, will be self-administered, 2 drops into each eye four times (QID) a day for ninety (90) days.

  • PI and Patient MaskedOther

    Both the PI and the participant are masked on the drug administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes from Baseline utilizing University of North Carolina Dry Eye Management Scale (UNC DEMS) ScoresTime frame: Through study completion, an average of 4 months.
  2. Changes from Baseline utilizing Ocular Surface Disease Index (OSDI)Time frame: Through study completion, an average of 4 months.

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Beverly Hills Institute of Ophthalmology

    Beverly Hills, California

  • Beach Eye Medical Group

    Huntington Beach, California

  • Regenerative Ocular Immunobiologics, LLC.

    Palm Harbor, Florida

  • Glenn Eye Center

    Lexington, Kentucky

  • Eyewell, LLC.

    Boston, Massachusetts

  • BostonSight

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.